Key Points
- Different stance: Indonesia will not ban vapes; the focus is on controlling narcotic or psychotropic substances in vape liquids.
- Seizure: Around 1,800 vape devices recently confiscated, containing etomidate and ketamine.
- Cooperation: BNN is working with customs, marketplaces, and vape shops to strengthen supervision.
- Singapore comparison: On August 17, Singapore Prime Minister Lawrence Wong announced that vaping would be treated as a “drug issue” with harsher penalties.
According to a Tempo report on August 22, Indonesia’s National Narcotics Agency (BNN) confirmed it will not follow Singapore’s move to impose a blanket ban on e-cigarettes. On August 21, BNN Chief Marthinus Hukom told the media that Indonesia’s focus is on tightening control over vape liquids containing hazardous substances, rather than banning vaping devices themselves.
Hukom revealed that BNN had recently seized about 1,800 vaping devices laced with etomidate and ketamine. Laboratory analysis confirmed that these substances are classified as anesthetics and fall under the psychotropic category. The cases were then handed over to the National Agency of Drug and Food Control (BPOM) and the police.
He stressed that while e-cigarettes have evolved from traditional tobacco products, they are also being misused as a new method of drug abuse. BNN is now collaborating with customs, e-commerce platforms, and vape shops to enhance market monitoring. Hukom emphasized:
“What is banned is the narcotics, not the vape.”
In contrast, Singapore has recently tightened its stance. On August 17, Prime Minister Lawrence Wong declared in his National Day address that vaping will now be treated as a drug-related issue, with stricter penalties including imprisonment. Wong noted that although vaping has been banned since 2018, smuggling remains rampant, and many products contain hazardous substances such as etomidate, known locally as “Kpods.”
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
